{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:57:40Z","timestamp":1780952260419,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00774-025-01689-6","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:45:59Z","timestamp":1767584759000},"page":"354-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between femoral localized cortical thickening (\u201cbeaking\u201d or \u201cflaring\u201d) and bisphosphonate duration in glucocorticoid-induced osteoporosis"],"prefix":"10.1007","volume":"44","author":[{"given":"Yudai","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-9677","authenticated-orcid":false,"given":"Sachiko","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Uchihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Akai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"e214920","DOI":"10.1001\/jamanetworkopen.2021.4920","volume":"4","author":"BI Wallace","year":"2021","unstructured":"Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK (2021) Prevalence of immunosuppressive drug use among commercially insured US adults, 2018\u20132019. JAMA Netw Open 4:e214920","journal-title":"JAMA Netw Open"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.berh.2009.09.006","volume":"23","author":"C Kok","year":"2009","unstructured":"Kok C, Sambrook PN (2009) Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin Rheumatol 23:769\u2013779","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S et al (2024) The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab 42:143\u2013154","journal-title":"J Bone Miner Metab"},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20780","volume":"20","author":"S Davis","year":"2016","unstructured":"Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 20:1\u2013406","journal-title":"Health Technol Assess"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/j.1532-5415.2011.03571.x","volume":"59","author":"AN Pham","year":"2011","unstructured":"Pham AN, Datta SK, Weber TJ, Walter LC, Col\u00f3n-Emeric CS (2011) Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy. J Am Geriatr Soc 59:1642\u20131649","journal-title":"J Am Geriatr Soc"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Adams J, Borgstr\u00f6m F, Cooper C, J\u00f6nsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4\u201315","journal-title":"Bone"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304\u20131306","journal-title":"N Engl J Med"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","volume":"27","author":"RM Dell","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544\u20132550","journal-title":"J Bone Miner Res"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jama.2011.190","volume":"305","author":"LY Park-Wyllie","year":"2011","unstructured":"Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783\u2013789","journal-title":"JAMA"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","volume":"172","author":"RP Meier","year":"2012","unstructured":"Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172:930\u2013936","journal-title":"Arch Intern Med"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1007\/s11999-010-1583-2","volume":"468","author":"YC Ha","year":"2010","unstructured":"Ha YC, Cho MR, Park KH, Kim SY, Koo KH (2010) Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 468:3393\u20133398","journal-title":"Clin Orthop Relat Res"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1007\/s11999-011-1828-8","volume":"469","author":"MB Banffy","year":"2011","unstructured":"Banffy MB, Vrahas MS, Ready JE, Abraham JA (2011) Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 469:2028\u20132034","journal-title":"Clin Orthop Relat Res"},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"S Shane E","year":"2014","unstructured":"Shane E S, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"5932496","DOI":"10.1155\/2017\/5932496","volume":"2017","author":"SP Jang","year":"2017","unstructured":"Jang SP, Yeo I, So SY, Kim K, Moon YW, Park YS, Lim SJ (2017) Atypical femoral shaft fractures in female bisphosphonate users were associated with an increased anterolateral femoral bow and a thicker lateral cortex: a case-control study. Biomed Res Int 2017:5932496","journal-title":"Biomed Res Int"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2106\/JBJS.23.01439","volume":"106","author":"PA Anderson","year":"2024","unstructured":"Anderson PA, Kates SL, Watts NB (2024) Update on atypical femoral fractures. J Bone Joint Surg Am 106:1819\u20131828","journal-title":"J Bone Joint Surg Am"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00198-015-3382-9","volume":"27","author":"H Sato","year":"2016","unstructured":"Sato H, Kondo N, Wada Y, Nakatsue T, Iguchi S, Fujisawa J, Kazama JJ, Kuroda T, Nakano M, Endo N, Narita I (2016) The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Osteoporos Int 27:1217\u20131225","journal-title":"Osteoporos Int"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00296-019-04407-4","volume":"39","author":"H Sato","year":"2019","unstructured":"Sato H, Kondo N, Wakamatsu A, Kobayashi D, Nakatsue T, Wada Y, Kuroda T, Suzuki Y, Nakano M, Endo N, Narita I (2019) High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Rheumatol Int 39:1803\u20131810","journal-title":"Rheumatol Int"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","volume":"86","author":"J Schilcher","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Micha\u00eblsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100\u2013107","journal-title":"Acta Orthop"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","volume":"20","author":"BA Lenart","year":"2009","unstructured":"Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353\u20131362","journal-title":"Osteoporos Int"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00223-014-9887-y","volume":"95","author":"LP Chen","year":"2014","unstructured":"Chen LP, Chang TK, Huang TY, Kwok TG, Lu YC (2014) The correlation between lateral bowing angle of the femur and the location of atypical femur fractures. Calcif Tissue Int 95:240\u2013247","journal-title":"Calcif Tissue Int"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335","journal-title":"J Bone Miner Res"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"e10749","DOI":"10.1002\/jbm4.10749","volume":"7","author":"T Kaku","year":"2023","unstructured":"Kaku T, Oh Y, Sato S, Koyanagi H, Funauchi Y, Hirai T, Yuasa M, Matsukura Y, Yoshii T, Nakagawa T, Miyake S, Okawa A (2023) Prevalence of precursory signs of atypical femoral fractures in patients receiving bone-modifying agents for bone metastases: a cross-sectional study. JBMR Plus 7:e10749","journal-title":"JBMR Plus"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/0971-3026.107178","volume":"22","author":"TP Jain","year":"2012","unstructured":"Jain TP, Thorn M (2012) Atypical femoral fractures related to bisphosphonate therapy. Indian J Radiol Imaging 22:178\u2013181","journal-title":"Indian J Radiol Imaging"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00774-014-0591-9","volume":"33","author":"Y Saita","year":"2015","unstructured":"Saita Y, Ishijima M, Mogami A, Kubota M, Baba T et al (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33:311\u2013318","journal-title":"J Bone Miner Metab"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMc0910389","volume":"362","author":"CM Girgis","year":"2010","unstructured":"Girgis CM, Sher D, Seibel MJ (2010) Atypical femoral fractures and bisphosphonate use. N Engl J Med 362:1848\u20131849","journal-title":"N Engl J Med"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743\u2013753","journal-title":"N Engl J Med"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","volume":"41","author":"RS Weinstein","year":"2012","unstructured":"Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 41:595\u2013611","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/art.30135","volume":"63","author":"SL Teitelbaum","year":"2011","unstructured":"Teitelbaum SL, Seton MP, Saag KG (2011) Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 63:325\u2013328","journal-title":"Arthritis Rheum"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000515542","volume":"7","author":"K Asadipooya","year":"2021","unstructured":"Asadipooya K, Abdalbary M, Ahmad Y, Kakani E, Monier-Faugere MC, El-Husseini A (2021) Bone quality in chronic kidney disease patients: current concepts and future directions - part II. Kidney Dis (Basel) 7:359\u2013371","journal-title":"Kidney Dis (Basel)"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/nep.14407","volume":"29","author":"M Marando","year":"2024","unstructured":"Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A (2024) Phosphorous metabolism and manipulation in chronic kidney disease. Nephrology (Carlton) 29:791\u2013800","journal-title":"Nephrology (Carlton)"},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bone.2014.01.011","volume":"62","author":"F Chen","year":"2014","unstructured":"Chen F, Wang Z, Bhattacharyya T (2014) Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures. Bone 62:64\u201366","journal-title":"Bone"},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/jbmr.2345","volume":"30","author":"R Niimi","year":"2015","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A (2015) Cortical thickness of the femur and long-term bisphosphonate use. J Bone Miner Res 30:225\u2013231","journal-title":"J Bone Miner Res"},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B (2016) The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85:142\u2013147","journal-title":"Bone"},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","volume":"27","author":"KE Naylor","year":"2016","unstructured":"Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R (2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the Trio study. Osteoporos Int 27:21\u201331","journal-title":"Osteoporos Int"},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtim\u00e4ki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Siev\u00e4nen H, Vuori I, V\u00e4\u00e4n\u00e4nen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804\u20131812","journal-title":"J Bone Miner Res"},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.injury.2016.09.031","volume":"47","author":"Y Iizuka","year":"2016","unstructured":"Iizuka Y, Iizuka H, Kaneko T, Mieda T, Takechi R (2016) Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients. Injury 47:2484\u20132489","journal-title":"Injury"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"19974","DOI":"10.1038\/s41598-024-71024-y","volume":"14","author":"J Ahn","year":"2024","unstructured":"Ahn J, Kim CH, Kim JW (2024) Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures. Sci Rep 14:19974","journal-title":"Sci Rep"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11914-021-00660-4","volume":"19","author":"DC Bauer","year":"2021","unstructured":"Bauer DC, Abrahamsen B (2021) Bisphosphonate drug holidays in primary care: when and what to do next? Curr Osteoporos Rep 19:182\u2013188","journal-title":"Curr Osteoporos Rep"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/jbmr.3523","volume":"33","author":"A Balasubramanian","year":"2018","unstructured":"Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR (2018) Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J Bone Miner Res 33:1881\u20131888","journal-title":"J Bone Miner Res"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3803\/EnM.2020.659","volume":"35","author":"JW Koh","year":"2020","unstructured":"Koh JW, Kim J, Cho H, Ha YC, Kim TY, Lee YK, Kim HY, Jang S (2020) Effects of systemic glucocorticoid use on fracture risk: a population-based study. Endocrinol Metab Seoul 35:562\u2013570","journal-title":"Endocrinol Metab Seoul"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00198-021-05948-w","volume":"32","author":"KD Gu","year":"2021","unstructured":"Gu KD, Ettinger B, Grimsrud CD, Lo JC (2021) Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy. Osteoporos Int 32:2119\u20132123","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01689-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:02:25Z","timestamp":1780948945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01689-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}